癌症免疫治疗学会关于免疫治疗晚期肾细胞癌（RCC）的共识声明。
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).
机构信息
Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA.
KCCure, Leesburg, VA, USA.
出版信息
J Immunother Cancer. 2019 Dec 20;7(1):354. doi: 10.1186/s40425-019-0813-8.
The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approved as monotherapy in 2015 for aRCC after treatment with a VEGF-targeting agent. In April 2018, the combination of nivolumab and ipilimumab, a CTLA-4 inhibitor, was approved for intermediate- and poor-risk, previously untreated patients with aRCC. Then, in 2019, combinations therapies consisting of pembrolizumab (anti-PD-1) or avelumab (anti-PD-ligand (L) 1) with axitinib (a VEGF receptor tyrosine kinase inhibitor) were also approved to treat aRCC and are likely to produce dramatic shifts in the therapeutic landscape. To address the rapid advances in immunotherapy options for patients with aRCC, the Society for Immunotherapy of Cancer (SITC) reconvened its Cancer Immunotherapy Guidelines (CIG) Renal Cell Carcinoma Subcommittee and tasked it with generating updated consensus recommendations for the treatment of patients with this disease.
近年来，免疫治疗药物和基于免疫疗法的联合治疗策略的获批彻底改变了晚期肾细胞癌（aRCC）患者的治疗模式。纳武利尤单抗（nivolumab）是一种程序性死亡受体 1（PD-1）免疫检查点抑制剂单克隆抗体，2015 年在接受血管内皮生长因子（VEGF）靶向药物治疗后，被批准用于 aRCC 的单药治疗。2018 年 4 月，纳武利尤单抗联合 CTLA-4 抑制剂伊匹单抗（ipilimumab）获批用于中危和高危、未经治疗的 aRCC 患者。随后，在 2019 年，派姆单抗（anti-PD-1）或avelumab（anti-PD-配体（L）1）联合阿昔替尼（VEGF 受体酪氨酸激酶抑制剂）的联合治疗方案也被批准用于治疗 aRCC，这可能会极大地改变治疗格局。为了应对 aRCC 患者免疫治疗方案的快速发展，癌症免疫治疗学会（SITC）重新召集其癌症免疫治疗指南（CIG）肾细胞癌小组委员会，并责成其制定更新的共识建议，以治疗该疾病患者。
Zotero 插件